

**DIASORIN LAUNCHES ITS NEW TEST TO ACCURATELY DETECT SEVERE BACTERIAL INFECTIONS (e.g. Sepsis): THE LIAISON BRAHMS PCT II GEN FOR THE QUANTITATIVE DETERMINATION OF PROCALCITONIN.**

April 29, 2015 - Saluggia (VC) - DiaSorin (FTSE Italia Mid Cap:DIA) is pleased to announce that it has launched the **LIAISON BRAHMS PCT II GENERATION** assay, developed in agreement with B·R·A·H·M·S GmbH, for the diagnosis of severe bacterial infections like sepsis through the quantitative determination of Procalcitonina (PTC), available on the market outside the US.

Procalcitonin is produced by the body as a result of sepsis and is useful in diagnosis because it helps differentiating patients with sepsis from those with a systemic inflammatory response syndrome. In fact, PCT is internationally recognised as the primary diagnostic marker for the early detection of sepsis in critically ill patients.

Sepsis is a systemic inflammation caused by uncontrolled bacterial infection. Despite advances in modern medicine, including antibiotics and vaccines, sepsis still affects between 20 and 30 million people every year and remains the primary cause of death from infection. The mortality rate of sepsis, between 30% and 60% of ill, is in fact higher than bowel and breast cancer combined.

In order to effectively manage sepsis, early diagnosis is crucial for patients' lives and for costs' control. A research published in *Critical Care Medicine* showed that each hour of delay in therapy can decrease chances of patient survival by 7.6%, which makes rapid and reliable detection of sepsis a national, if not global, imperative.

As for costs, an early diagnosis reduces the financial burden of sepsis therapy that today represents a struggle for hospitals. For example, in the U.S., hospital costs associated with treating severe sepsis are estimated around \$16 billion annually and much of this cost is attributed to delayed or misdiagnosis.

Chen Even, Senior Corporate VP Commercial Operations of DiaSorin, commented: "Our new **LIAISON BRAHMS PCT II GEN** test will offer health-care professionals an integrated solution for accurate detection of severe bacterial infections such as sepsis, significantly improving medical decision-making. Furthermore, our test will expand our CLIA specialty menu providing a high sensitive, specific and fast automated test of high medical value for clinicians".



REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	LIAISON® BRAHMS PCT® II GEN		
Diagnosis	Sepsis		
Business segment	Immunodiagnosics	✓	Molecular Diagnostics
Potential market	120 mln tests worldwide		
Technology	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		
Clinical Area	Infectious Diseases	✓	Infectious Diseases
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		
	Bone & Mineral		Onco-hematology
	Cardiac Markers		
	GI Stool Testing		

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

**Riccardo Fava**  
 Investor Relations & Corporate Communication Director  
 Tel: +39.0161.487988  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Margherita Sacerdoti**  
 Investor Relations Specialist  
 Tel: +39.0161.487456  
[margherita.sacerdoti@diasorin.it](mailto:margherita.sacerdoti@diasorin.it)